[go: up one dir, main page]

WO2009071680A3 - Composés d'antagonistes d'arn utiles pour moduler mcl-1 - Google Patents

Composés d'antagonistes d'arn utiles pour moduler mcl-1 Download PDF

Info

Publication number
WO2009071680A3
WO2009071680A3 PCT/EP2008/066920 EP2008066920W WO2009071680A3 WO 2009071680 A3 WO2009071680 A3 WO 2009071680A3 EP 2008066920 W EP2008066920 W EP 2008066920W WO 2009071680 A3 WO2009071680 A3 WO 2009071680A3
Authority
WO
WIPO (PCT)
Prior art keywords
mcl
modulation
expression
antagonist compounds
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/066920
Other languages
English (en)
Other versions
WO2009071680A2 (fr
Inventor
Jens Bo Hansen
Anja Moelhart Hoeg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Innovation Center Copenhagen AS
Original Assignee
Santaris Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santaris Pharma AS filed Critical Santaris Pharma AS
Priority to US12/746,745 priority Critical patent/US20100323967A1/en
Priority to JP2010536479A priority patent/JP2011505798A/ja
Priority to EP08855783A priority patent/EP2238249A2/fr
Publication of WO2009071680A2 publication Critical patent/WO2009071680A2/fr
Publication of WO2009071680A3 publication Critical patent/WO2009071680A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

On a mis au point des oligonucléotides dirigés contre le gène Mcl-1 afin de moduler l'expression de la protéine Mcl-1. Les compositions comprennent des oligonucléotides, notamment des oligonucléotides antisens, ciblés sur des acides nucléiques codant Mcl-1. Cette invention porte également sur des méthodes d'utilisation de ces composés en vue de moduler l'expression de Mcl-1 et pour le traitement de maladies associées à la surexpression de Mcl-1. Des exemples de ces maladies sont le cancer et la mastocytose généralisée.
PCT/EP2008/066920 2007-12-07 2008-12-05 Composés d'antagonistes d'arn utiles pour moduler mcl-1 Ceased WO2009071680A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/746,745 US20100323967A1 (en) 2007-12-07 2008-12-05 RNA Antagonist Compounds for the Modulation of MCL-1
JP2010536479A JP2011505798A (ja) 2007-12-07 2008-12-05 Ｍｃｌ−１を調節するためのＲＮＡアンタゴニスト化合物
EP08855783A EP2238249A2 (fr) 2007-12-07 2008-12-05 Composés d'antagonistes d'arn utiles pour moduler mcl-1

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1219107P 2007-12-07 2007-12-07
US61/012,191 2007-12-07
US9595508P 2008-09-11 2008-09-11
US61/095,955 2008-09-11

Publications (2)

Publication Number Publication Date
WO2009071680A2 WO2009071680A2 (fr) 2009-06-11
WO2009071680A3 true WO2009071680A3 (fr) 2009-07-23

Family

ID=40329152

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/066920 Ceased WO2009071680A2 (fr) 2007-12-07 2008-12-05 Composés d'antagonistes d'arn utiles pour moduler mcl-1

Country Status (4)

Country Link
US (1) US20100323967A1 (fr)
EP (1) EP2238249A2 (fr)
JP (1) JP2011505798A (fr)
WO (1) WO2009071680A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2907694A1 (fr) * 2013-05-24 2014-11-27 Roche Innovation Center Copenhagen A/S Modulateurs oligonucleotidiques de la leucemie lymphocytaire chronique a cellules b/lymphome 11a (bcl11a) et utilisations de ceux.ci
WO2017184082A1 (fr) * 2016-04-22 2017-10-26 Nanyang Technological University Oligonucléotide chimère de perméation de lymphocytes, procédés et utilisations associés
US11065230B2 (en) 2016-09-16 2021-07-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of systemic mastocytosis
WO2018181428A1 (fr) 2017-03-29 2018-10-04 塩野義製薬株式会社 Complexe de médicament d'acide nucléique et de lipide multiramifié
EP4005602A4 (fr) 2019-07-30 2024-06-12 Shionogi & Co., Ltd Médicament à base d'acide nucléique ciblant le murf1
JP7751302B2 (ja) 2020-06-15 2025-10-08 リードファーマ株式会社 架橋型ヌクレオシドおよびヌクレオチド

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001511000A (ja) * 1997-01-31 2001-08-07 バイオグノスティック ゲゼルシャフト フュア バイオモレキュラー ダイアグノスティック ミット ベシュレンクテル ハフツング アンチセンスオリゴヌクレオチドの製造方法
WO2004048511A2 (fr) * 2002-11-26 2004-06-10 Rosetta Genomics Ltd. Groupe detectable par bio-informatique, de nouveaux genes regulateurs viraux, et utilisations de ceux-ci
WO2007109174A2 (fr) * 2006-03-16 2007-09-27 Isis Pharmaceuticals, Inc. Compositions et procedes de modulation de l'expression de mcl-1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711919D0 (en) * 1997-06-09 1997-08-06 Ciba Geigy Ag Oligonucleotide derivatives
WO2007136989A2 (fr) * 2006-05-05 2007-11-29 Isis Pharmaceuticals, Inc. Composés et procédés pour moduler l'expression de dgat2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001511000A (ja) * 1997-01-31 2001-08-07 バイオグノスティック ゲゼルシャフト フュア バイオモレキュラー ダイアグノスティック ミット ベシュレンクテル ハフツング アンチセンスオリゴヌクレオチドの製造方法
WO2004048511A2 (fr) * 2002-11-26 2004-06-10 Rosetta Genomics Ltd. Groupe detectable par bio-informatique, de nouveaux genes regulateurs viraux, et utilisations de ceux-ci
WO2007109174A2 (fr) * 2006-03-16 2007-09-27 Isis Pharmaceuticals, Inc. Compositions et procedes de modulation de l'expression de mcl-1

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
AICHBERGER K J ET AL: "Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: Inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 109, no. 7, 1 April 2007 (2007-04-01), pages 3031 - 3041, XP002478480, ISSN: 0006-4971 *
DATABASE EMBL [online] 14 December 2007 (2007-12-14), "Sequence 137 from Patent WO2007109174.", XP002514972, retrieved from EBI accession no. EMBL:CS811835 Database accession no. CS811835 *
DATABASE EMBL [online] 14 December 2007 (2007-12-14), "Sequence 138 from Patent WO2007109174.", XP002514973, retrieved from EBI accession no. EMBL:CS811836 Database accession no. CS811836 *
DATABASE EMBL [online] 29 December 2008 (2008-12-29), "SINGLE-STRANDED ANTIMICROBIAL OLIGONUCLEOTIDES AND USES THEREOF.", XP002514974, retrieved from EBI accession no. EMBL:DL465760 Database accession no. DL465760 *
DATABASE EMBL [online] 4 September 2002 (2002-09-04), "An antisense oligonucleotide preparation method.", XP002514976, retrieved from EBI accession no. EMBL:BD065789 Database accession no. BD065789 *
DATABASE Geneseq [online] 16 January 2002 (2002-01-16), "Validation ribozyme DNA sequence #92.", XP002514977, retrieved from EBI accession no. GSN:AAS56918 Database accession no. AAS56918 *
DATABASE Geneseq [online] 28 December 2007 (2007-12-28), "Viral regulatory miRNA SEQ ID NO 128283.", XP002514975, retrieved from EBI accession no. GSN:AJI75962 Database accession no. AJI75962 *
JANSEN B ET AL: "Antisense therapy for cancer-the time of truth", LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 3, no. 11, 1 November 2002 (2002-11-01), pages 672 - 683, XP004810743, ISSN: 1470-2045 *
MOTT J L ET AL: "mir-29 regulates Mcl-1 protein expression and apoptosis", ONCOGENE, NATURE PUBLISHING GROUP, GB BASINGSTOKE, HANTS, vol. 26, no. 42, 12 April 2007 (2007-04-12), pages 6133 - 6140, XP002499484, ISSN: 0950-9232, [retrieved on 20070402] *
THALLINGER CHRISTIANE ET AL: "Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model.", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY JUN 2003, vol. 120, no. 6, June 2003 (2003-06-01), pages 1081 - 1086, XP002515069, ISSN: 0022-202X *
WACHECK VOLKER ET AL: "Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells", CANCER BIOLOGY AND THERAPY, LANDES BIOSCIENCE, US, vol. 5, no. 10, 1 October 2006 (2006-10-01), pages 1348 - 1354, XP008084402, ISSN: 1538-4047 *

Also Published As

Publication number Publication date
US20100323967A1 (en) 2010-12-23
JP2011505798A (ja) 2011-03-03
EP2238249A2 (fr) 2010-10-13
WO2009071680A2 (fr) 2009-06-11

Similar Documents

Publication Publication Date Title
WO2012075040A3 (fr) Arnm pour l'utilisation dans le traitement de maladies génétiques humaines
NO20081884L (no) Modulasjon av glukagonreseptorekspresjon
WO2008043753A3 (fr) Composés antagonistes de l'arn pour la modulation de pcsk9
EA200800868A1 (ru) Модуляция экспрессии глюкокортикоидного рецептора
WO2007095316A3 (fr) Compositions et procédés pour formulations à base d'oligonucléotides
WO2009046141A3 (fr) Modulation antisens de l'expression du récepteur 4 du facteur de croissance des fibroblastes
WO2005005599A3 (fr) Modulation de l'expression de la proteine c-reactive
WO2004071407A3 (fr) Modulation antisens de l'expression de ptp1b
WO2005049630A3 (fr) Modulation antisens de l'expression de la proteine de type kinesine 1
HK1201514A1 (en) Functionally-modified oligonucleotides and subunits thereof
WO2009129319A3 (fr) Réduction au silence de l'expression du gène csn5 au moyen d'arn interférant
WO2009006577A3 (fr) Compositions et méthodes pour inhiber la protéine ezh2
WO2004044181A3 (fr) Modulation antisens de l'expression d'apolipoproteine b
WO2007064857A8 (fr) Formulation de liposomes amphoteres
WO2004011610A3 (fr) Modulation antisens de l'expression de kinase de type polo
WO2008153933A3 (fr) Protéines à variante d'épissure her2 et her3 solubles, oligonucléotides à permutation d'épissage et leur utilisation thérapeutique
WO2003097662A8 (fr) Modulation antisens de l'expression de l'apolipoproteine b
WO2006026485A3 (fr) Modulation de l'expression de hif1 beta
WO2009071680A3 (fr) Composés d'antagonistes d'arn utiles pour moduler mcl-1
WO2005071080A3 (fr) Modulation de l'expression du récepteur glucocorticoïde
WO2004009024A3 (fr) Modulation de l'expression de la proteine kinase c-iota
WO2007014077A3 (fr) Modulation de l'arni du gene rho-a et utilisations de celle-ci
WO2005014607A3 (fr) Modulation antisens de l'expression de la stearoyl-coa desaturase
WO2004010956A3 (fr) Modulation par antisens d'expression de lar
WO2007062380A3 (fr) MODULATION DE L'EXPRESSION D’eIF4E-BP2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08855783

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010536479

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008855783

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12746745

Country of ref document: US